MAPT and Alzheimer disease: Additionally, cerebrospinal fluid and markers of AD pathophysiology (amyloid, tau, and neuronal injury) have been found to predict progression but were not included in the MNL prediction models because biomarker and imaging data are missing for most NACC participants [58, 59].